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INTRODUCTION
Coronavirus disease-2019 (COVID-19) is a novel respiratory 
infectious disease caused by severe acute respiratory syndrome 
coronavirus 2 (SARS-CoV-2). In the absence of effective con-
firmed therapy, empirical and experimental treatments for SARS 
have mainly taken place.1-10 Convalescent plasma (CP), do-
nated by people who have recovered from COVID-19, is an in-
vestigational therapy for severe or critically ill patients with CO-
VID-19. CP therapy has been used to treat patients with other 
viral infections, such as infections caused by the H1N1 influ-
enza A virus, Argentinian mammarenavirus, Lassa mammare-
navirus, Middle East respiratory syndrome coronavirus (MERS-
CoV), SARS-CoV-1, and Ebola virus.11-13 The use of plasma 
from recovered patients has demonstrated clinical benefits in 
those with severe or life-threatening COVID-19, despite some 
methodological limitations in previous studies.14-16 Although 
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the use of CP has shown favorable results in many cases, evi-
dence supporting its use in the treatment of COVID-19 remains 
insufficient.17-20 Therefore, in this study, we aimed to evaluate 
the effectiveness and safety of CP therapy in severe or critically 
ill patients and the changes in viral load clearance based on 
cycle threshold (Ct) values over time between patients who re-
ceived and did not receive CP.
MATERIALS AND METHODS
Study design and subjects
A retrospective study was conducted to evaluate the clinical 
outcomes of CP therapy in patients with severe or life-threat-
ening COVID-19 at two hospitals in Seoul, Korea, between 
May and September 2020. Clinical outcomes were evaluated 
in 20 patients who received CP therapy in a descriptive manner. 
Simultaneously, the changes in Ct values of 10 patients who re-
ceived CP transfusions were compared to those of 10 control 
patients who did not receive CP therapy. Patients with laborato-
ry-confirmed cases of COVID-19, which were diagnosed using 
quantitative reverse transcriptase polymerase chain reaction 
(qRT-PCR), were eligible to receive CP treatment if they fulfilled 
the following criteria: 1) signed informed consent, 2) showed 
findings of pneumonia on imaging studies, and 3) had clinical 
features meeting the definitions of severe or life-threatening 
COVID-19. Severe COVID-19 was defined as respiratory dis-
tress with a respiratory rate of ≥30 breaths/min in the resting 
state, desaturation of ≤93% on room air, or arterial partial pres-
sure of oxygen (PaO2)/fraction of inspired oxygen (FiO2) ≤300 
mm Hg. Life-threatening COVID-19 was defined as respiratory 
failure requiring mechanical ventilation, septic shock, or mul-
tiple organ failure (organs other than the lungs) requiring in-
tensive care unit monitoring. 
Patients who were infected with SARS-CoV-2 but did not re-
ceive CP were enrolled in the control group for the comparison 
of viral load clearance. Within the ±0.8 range, these patients 
were conditioned to have the same initial Ct values as those in 
the CP group. Patients with CP were matched 1:1 with those 
who did not undergo CP with the same (±0.8) Ct value. The 
initial Ct values in both groups ranged between 19 and 34. The 
severity of the disease was not considered when matching the 
two groups. 
Convalescent plasma therapy
All donors had been previously diagnosed with laboratory-
confirmed COVID-19, and treated at the Seoul Medical Center. 
An information leaflet about CP donation was distributed to 
COVID-19 patients who were scheduled to be discharged. 
Those who announced intension to donate CP allowed the 
medical staffs to call them after discharge. After reconfirming 
their volition of donation on the line, plasmapheresis for each 
donor was scheduled. They had subsequently tested negative 
for SARS-CoV-2 and other viruses, such as hepatitis B virus, 
hepatitis C virus, and human immunodeficiency virus, and for 
syphilis at the time of plasma donation. After providing their 
written informed consent on the day of the plasmapheresis, the 
donors gave their CP. Afterwards, 500 mL of CP was collected 
from each donor by apheresis and stored in a frozen state. It 
was administered to the recipients after thawing. The ABO 
blood types of the patients were determined for potential com-
patibility with the CP donor. Except for two cases, each patient 
received two consecutive transfusions of 250 mL of ABO-com-
patible CP. 
The levels of neutralizing antibodies against SARS-CoV-2 in 
donor plasma were measured by the plaque reduction neu-
tralization test. Ten-fold serial dilutions of the virus stock were 
prepared in a virus dilution medium. A confluent monolayer of 
Vero cells was infected with serial dilutions of SARS-CoV-2 
samples with an unknown starting concentration. After adsorp-
tion, an immobilizing overlay was used to cover the infected 
monolayer to prevent virus spread and restrict virus growth to 
the foci of cells at the sites of initial infection. During incubation, 
the zones of cell death developed as viral infection and replica-
tion were restricted to the surrounding monolayer, leading to 
plaque formation. After incubation, the cells were stained to en-
hance contrast between plaques and the uninfected monolayer. 
Plaques were then enumerated and used to calculate the titer 
of the infectious virus in the specimen. 
Data collection 
Data on the following parameters were collected: demograph-
ics; days to admission from symptom onset; therapeutic mo-
dalities including high-dose oxygen therapy, antiviral therapies, 
and steroids; clinical parameters including National Institutes 
of Health (NIH) severity scores, World Health Organization 
(WHO) ordinal scale scores, and PaO2/FiO2 ratios; laboratory pa-
rameters including white blood cell counts, lymphocyte counts, 
C-reactive protein (CRP) levels, and Ct values for SARS-CoV-2; 
and findings of chest imaging studies. Remdesivir was admin-
istered for 5 days. Steroids treatment for more than 1 day was 
counted to therapeutic modalities. Nasopharyngeal swabs (NP) 
and sputum samples were serially collected from 20 patients 
receiving CP transfusions 1 day before the CP therapy and on 
the 1st and 3rd day after CP therapy. The same types of speci-
mens were also serially collected from COVID-19 patients who 
did not receive CP therapy on the admission day, as well as on 
the 1st and 3rd day after admission. qRT-PCR for SARS-CoV-2 
was performed using NP and sputum specimens. Real-time 
RT-PCR assay targeting the three genes (RdRp, N, and E genes) 
of SARS-Cov-2 was performed with a Seegene Kit (Allplex 2019-
nCoV Assay kit, Seegene, Seoul, Korea). 
Clinical outcomes and changes in viral loads within a 28-day 
period were evaluated. The improvement of disease severity 
scale scores, change in the PaO2/FiO2 ratio, and any adverse 
events, including transfusion-related adverse events, were also 
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evaluated. 
The WHO ordinal scale scores were classified as follows: 8 
points, death; 7 points, hospitalization plus extracorporeal mem-
brane oxygenation or invasive mechanical ventilation; 6 points, 
hospitalization and the requirement of high-flow nasal cannu-
las (HFNC) or non-invasive ventilation; 5 points, hospitalization 
with any supplemental oxygen therapy; 4 points, hospitaliza-
tion with ongoing medical care but without oxygen therapy; 
3 points, hospitalization without oxygen therapy and ongoing 
medical care, 2 points; ambulation with limited activity or with 
home oxygen support; and 1 point, ambulation with unlimited 
activity. 
Disease severity according to the NIH severity scale was clas-
sified as follows: 
1) Asymptomatic or pre-symptomatic infection: individuals 
testing positive for SARS-CoV-2 but not showing symptoms
2) Mild illness: individuals with any of the various signs and 
symptoms of COVID-19 but without shortness of breath, dys-
pnea, or abnormal chest imaging findings
3) Moderate illness: individuals with evidence of lower re-
spiratory disease on clinical assessment or imaging and oxy-
gen saturation (SpO2) of ≥94% on room air at sea level
4) Severe illness: individuals with a respiratory rate of >30 
breaths per minute, SpO2 of <94% on room air at sea level, a 
PaO2/FiO2 ratio of ≤300 mm Hg, or lung infiltrates of >50%
5) Critical illness: individuals with respiratory failure, septic 
shock, and/or multiple organ dysfunction
Statistical analysis 
All variables are expressed as the mean (range) or number (per-
centage), unless otherwise indicated. The longitudinal data of 
Ct values in the matching groups were compared using a linear 
mixed model. Statistical significance was set at a p value<0.05. 
Statistical analysis was performed using the Statistical Package 
for Social Sciences software (version 25.0; IBM Corp., Armonk, 
NY, USA). 
Ethics statement
This study was approved by the Institutional Review Board of 
the Yonsei University Health System Clinical Trial Center (4-
2020-0263). Informed consent forms were signed by the partici-
pants who were willing to receive CP therapy and participate in 
the necessary research studies. 
RESULTS
Clinical outcomes in patients receiving convalescent 
plasma therapy
Table 1 shows the clinical characteristics of patients who re-
ceived CP therapy. The mean age was 66.6 years, and the sex 
ratio (male: female) was 11:9. Of all patients, 65% were critical-
ly ill according to the NIH severity criteria. Findings of pneu-
monia were observed on the initial chest imaging studies of all 
20 patients. All patients had a PaO2/FiO2 ratio ≤300 mm Hg. 
Eighteen patients (90%) required supplemental high-dose ox-
ygen via mechanical ventilators or HFNC. Nineteen patients 
(95%) received systemic steroids therapy. Five patients initial-
ly received combination therapy with steroids and remdesivir. 
The average duration from admission to convalescent thera-
py was 5.55 days, and that from symptom onset to CP was 11.5 
days. In the initial laboratory assessment, lymphopenia was 
noted in 15 patients. The mean levels of CRP and lactate dehy-
drogenase (LDH) were 10.39±7.11 and 455.36±125.88, respec-
tively. The neutralizing antibody titers of the administered CP 
Table 1. Baseline Characteristics of Patients with CP Therapy (n=20)
Characteristics Values 




Hypertension only 4 (20)
Cardiovascular diseases 2 (10)
Diabetes mellitus 3 (15)
Malignancy 1 (5)
Pneumonia on chest image 20 (100)
O2 supply
No oxygen 1 (5)
Nasal O2 cannula 1 (5)
High flow nasal cannula 5 (25)
Mechanical ventilator 13 (65)
Admission to CP, days 5.55 (±3.38)






CRP, mg/dL 10.26 (±6.99)
LDH, U/L 455.37 (±130.8)
Combined treatments
Remdesivir 5 (25)
Systemic steroid 19 (95)








CP, convalescent plasma; NHI, National Institute of Health; CRP, C-reactive 
protein; LDH, lactate dehydrogenase; SD, standard deviation.
Values are expressed as the n (%) or mean (±SD). 
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were between 1:80 and 1:10240. Eighty percent of the donated 
CP samples had a neutralizing antibody titer of ≥1:160. More 
significant Ct value change was not associated with a higher 
neutralizing antibody titer. Overall, there was no prognostic 
difference according to the neutralizing antibody titers.
The PaO2/FiO2 ratio was improved among all survivors in 14 
days (mean PaO2/FiO2 ratio on day 1: mean PaO2/FiO2 ratio 
on day 14=189.73:232.34) (Table 2). 
The WHO ordinal scale score and NIH severity score were 
improved in half of the patients within 14 days of CP transfu-
sion. Five patients (25%) showed a reduction of 2 points with-
in 14 days. The overall mortality rate among patients who re-
ceived CP therapy was 25%. One patient (5%) died within 7 days 
of plasma transfusion (on day 4 post-transfusion). The other four 
deaths occurred on days 11, 15, 28, and 60 after transfusion. All 
patients died due to COVID-19-related complications. 
Among the 20 CP recipients, two patients received ABO-
mismatched transfusions. One recipient with ABO type O re-
ceived CP from a donor with blood type B, and the other recipi-
ent with ABO type AB had CP from a donor with blood type A. 
No suspected transfusion-related adverse events were reported. 
Comparison of viral load clearance between patients 
who did and did not receive convalescent plasma
Table 3 shows the baseline characteristics of the 10 patients 
who received CP therapy and were matched with 10 controls 
based on similar initial Ct values. The most patients in both 
groups were in their 60s. All 10 patients who received CP were 
severely ill. In contrast, none of the 10 patients in the control 
group were severely ill. Four patients in the control group re-
quired oxygen support via nasal cannula and were treated 
with remdesivir for 5 days, but none of them received steroids. 
Patients who received CP required high-dose oxygen therapy. 
Sixty percent of the patients in the control group were treated 
without oxygen supplementation. All 20 patients initially had 
lymphopenia. The average CRP and LDH values were higher 
in the CP group than in the control group (Table 3). 
The initial Ct values of the E gene from nasopharyngeal 
specimens of patients who received CP ranged from 20.09 to 
35. At 24 h after CP therapy, Ct values of the E gene increased 
to range between 26.19 and 45. On comparing the Ct values of 
10 patients at 24 h and 72 h after CP therapy with 10 control pa-
tients who did not receive CP therapy, the viral load clearance 
was higher in patients who received CP (p=0.002). The com-
parison of Ct values of the E gene of two groups are shown in 
Fig. 1. In many study participants, Ct values were not mea-
sured consistently on the 5th, 7th, 14th, and 28th day. For this 
reason, the Ct values were indicated until the 3rd day in Fig. 1. 
The average initial Ct values of all 20 patients with CP was 
27.2. The mean Ct values were increasing day after day, even-
tually exceeding 35 on the 7th day after CP, and indicated low 
infectivity. The average initial Ct value of 10 patients who did 
not belong to the comparison group of Ct values was 26.14. The 
average initial Ct value of other 10 patients in the comparison 
group was 28.26. On the 1st day, the average Ct values among 
these patients were 33.4 and 31.2, respectively. Of the total five 
cases of mortality, four cases occurred in the selected group. 
Table 3. Baseline Characteristics of Patients with and without CP Who 
Had Similar Initial Ct Values
Characteristics With CP (n=10) Without CP (n=10)
Mean age, yr (range) 65.3 (44–83) 62.8 (31–81)
Male 7 (70) 5 (50)
Underlying diseases
None 3 (30) 5 (50)
Hypertension only 1 (10) 0 (0)
Cardiovascular diseases 1 (10) 1 (10)
Diabetes mellitus 2 (20) 2 (20)
Malignancy 1 (10) 0 (0)
Pneumonia on chest image 10 (100) 6 (60)
O2 supply
No oxygen 0 (0) 6 (60)
Nasal O2 cannula 0 (0) 4 (40)
High flow nasal cannula 4 (40) 0 (0)
Mechanical ventilator 6 (60) 0 (0)
NIH severity
Moderate 0 (5) 6 (60)
Severe 3 (30) 0 (0)
Critical 7 (70) 0 (0)
Remdesivir 3 (30) 4 (40)
Steroids 10 (100) 0 (0)
Lymphopenia 6 (60) 6 (60)
CRP, mg/dL 10.23 (±8.4) 3.56 (±4.5)
LDH, IU/L 481.44 (±119.14) 362.4 (±87.98)
NIH, National Institute of Health; CP, convalescent plasma; Ct, cycle thresh-
old value; CRP, C-reactive protein; LDH, lactate dehydrogenase; SD, standard 
deviation.
Values are expressed as the n (%) or mean (±SD). 
Table 2. Treatment Outcomes of Patients with Convalescent Plasma 
Therapy (n=20)
Outcomes Number of patients (%)
Mortality 
7-day mortality 1 (5)
14-day mortality 2 (10)
28-day mortality 4 (20)
Overall mortality 5 (25)
Improvement in severity within 7 days
WHO ordinal scale 8 (40)
NIH severity 5 (25)
Improvement in severity within 14 days
WHO ordinal scale 10 (50)
NIH severity 10 (50)
Improvement of P/F ratio among survivors 15 (100)
Transfusion-related adverse events 0 (0)
WHO, World Health Organization; NIH, National Institute of Health.
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Fig. 1. Comparison of viral loads clearance (E-gene) between patients 
with and without convalescent plasma (CP) (p=0.002). p value<0.05 was 
considered to indicated statistical significance.
DISCUSSION
Numerous studies have analyzed the effectiveness of CP ther-
apy for COVID-19. Some patients showed improved clinical 
outcomes. Increased oxygen saturation, recovery from lympho-
penia, and reduced inflammation were reported after CP treat-
ment in small studies.21-23 In a case series of five critically ill pa-
tients, Shen, et al.19 showed decreased viral loads and improved 
clinical conditions within days of plasma infusion. In several 
studies, a rapid reduction in viral load was reported.24,25 In this 
study, the SARS-CoV-2 load in the respiratory tract decreased 
at a higher rate in patients who received CP in a subgroup anal-
ysis involving a comparison with 10 patients who did not re-
ceive CP therapy. Viral loads were significantly lower at 24 h 
and 72 h after CP therapy. As assessed by the Ct values, the vi-
ral load declined within days of CP treatment, and the clinical 
condition of these patients improved. This provides evidence 
supporting CP transfusion as a valuable intervention in severe 
or critically ill COVID-19 patients. 
However, many studies have demonstrated no differences in 
mortality or disease severity between the treatment and control 
groups. In the ConCOVID study, an open-label randomized 
clinical trial of CP therapy versus the standard of care for hos-
pitalized COVID-19 patients, which was conducted in 14 hos-
pitals in the Netherlands, no differences in mortality or disease 
severity were observed between the groups on day 15.26 In the 
PLACID Trial, an open-label randomized clinical trial with 464 
participants, no superiority of CP therapy over the standard 
care was observed in terms of disease progression and 28-day 
mortality.27 In another randomized trial with 334 patients who 
were assigned in a 2:1 ratio to receive CP or a placebo, no mean-
ingful distinctions were found in the clinical status or overall 
mortality between the two groups.28 Similar to these studies, no 
significant difference in outcomes with CP therapy were ob-
served in the latest large-scale studies.29,30 The efficacy of CP 
therapy for COVID-19 remains controversial. Further research 
and experience regarding CP therapy are required to confirm 
its effectiveness. 
In several studies, the conditions and settings in which CP 
was more effective in COVID-19 patients were investigated. 
First, the timing of transfusion after symptom onset was evalu-
ated to optimize the effectiveness of CP therapy in multiple 
studies. Some studies have reported that better outcomes were 
associated with early transfusion therapy after the onset of 
symptoms.31-33 Joyner, et al.34 showed a significant reduction in 
mortality after the transfusion of CP with high antibody levels 
within 3 days of COVID-19 diagnosis. In addition, Joyner, et al.35 
reported in a different study that the risk of death within 30 
days was lower in patients who did not receive mechanical ven-
tilation but were treated with CP containing higher anti-SARS-
CoV-2 antibody levels. One retrospective case-control study 
suggested a trend toward the benefit of CP therapy among pa-
tients who were not intubated.15 In a randomized controlled tri-
al with elderly patients, it was reported that CP therapy in older 
patients reduced the risk of progression to severe respiratory 
disease when CP with high titers of antibodies was adminis-
tered within 72 h of symptom onset.36 Overall, treatment using 
CP with high titers of antibodies was beneficial against SARS-
CoV-2 infection among patients with a shorter duration of symp-
toms and those who were not intubated. Unfortunately, this 
study failed to show the correlation between better prognosis 
and higher neutralizing antibody titer of donors. The number of 
recipients was not large enough to evaluate the positive rela-
tionship between outcomes, and higher antibody levels in CP 
and early CP administration. A randomized trial with a larger 
number of recipients at multiple centers is needed to draw de-
finitive conclusions about the efficacy of CP for the treatment 
of COVID-19. 
The safety of CP treatment in severe COVID-19 patients has 
been a major concern in various studies. Serious transfusion-
related adverse events, such as allergic transfusion reactions, 
hemolytic transfusion reactions, transfusion-related acute lung 
injury, and transfusion-associated circulatory overload, can oc-
cur during CP therapy. In most studies, severe adverse events 
were uncommon.15,20,21,37-39 In this study, there was no evidence 
of serious adverse events or complications related to CP thera-
py, although ABO-mismatched transfusion occurred in two 
cases. This suggests that CP therapy is a safe method for treat-
ing COVID-19. 












Initial                                  Day 1                                     Day 3
  With CP (n=10)
  Without CP (n=10)
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symptoms of COVID-19, and steroids are known to lower mor-
tality in severely ill patients with COVID-19. In this study, rem-
desivir treatment was performed in almost the same number 
of patients in both groups. However, all 10 patients in CP group 
were treated with steroids, but none of the patients in the con-
trol group received steroids. The possibility could be consid-
ered that steroids may have contributed to lowering the viral 
loads. Spagnuolo, et al.40 showed that SARS-CoV-2 clearance 
was not associated with corticosteroid use in their study with 
280 moderate or severe COVID-19 patients. It is still hasty to 
conclude that the effects of steroids on viral loads are insignif-
icant, and additional research data regarding this topic should 
be accumulated. 
Similar to the majority of studies on CP therapy for severely 
ill COVID-19 patients, this study had a number of critical limi-
tations. First, this was a small study involving two healthcare 
centers with a non-randomized design. Therefore, it is unclear 
whether the clinical improvement observed in the 20 patients 
who received CP would have occurred without this treatment. 
Second, since nearly all of the patients were also treated with 
other medications, such as steroids or remdesivir, the extent 
to which the combined drug therapies affected the outcomes 
remains unclear. Third, the size of the donor pool was small. A 
larger donor pool would provide opportunities for severely ill 
patients to receive high-titer CP earlier in the disease course. 
Furthermore, the number of study participants were too small 
to indicate the correlation between clinical outcomes and high-
er antibody levels in CP and early CP administration among 
patients with or without ventilation care. Finally, matching with 
the control group was only based on similar initial Ct values. As 
other factors were not considered for matching, selection bias 
cannot be excluded. An important potential confounder in 
this analysis was the difference in disease severity between 
the two groups. This study was not objective enough to com-
pare the changes in Ct values between the two groups. Con-
sidering these limitations, additional studies are needed to 
confirm the beneficial findings and draw more definitive con-
clusions about the efficacy of CP transfusion for the treatment 
of COVID-19.
In conclusion, CP therapy might be a safe and potentially 
effective therapeutic option for improving the outcomes of se-
verely ill COVID-19 patients.
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